Clinical Trials Logo
  1. Home
  2. Brain Metastasis
  3. NCT02913534
  4. Details
NCT02913534 Clinical Trial

Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy

Brain Metastasis Clinical Trial

Official title:
Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02913534
Other study ID # ICL_2014_0001
Secondary ID
Status Completed
Phase N/A
First received September 22, 2016
Last updated September 22, 2016
Start date March 2014
Est. completion date June 2014

Study information
Verified date September 2016
Source Institut de Cancérologie de Lorraine
Contact n/a
Is FDA regulated No
Health authority France: Commission nationale de l'informatique et des libertés
Study type Observational

Clinical Trial Summary

The aim is to identify in patients with brain metastases the predictive factors of overall survival, survival without local recurrence and survival with progression-free brain metastases after complementary whole brain radiotherapy.

Recruitment information / eligibility
Status Completed
Enrollment 100
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with one to three brain metastases treated in our department with hypofractionated stereotactic radiotherapy (SRT) from March 2008 to February 2013.

Exclusion Criteria:

- A patient record captured after February 2013.

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Intervention

Radiation:
• whole brain radiotherapy

Locations
Country Name City State
France Institut de Cancerologie de Lorraine Vandoeuvre-les-Nancy

Sponsors (1)
Lead Sponsor Collaborator
Institut de Cancérologie de Lorraine

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Overall survival 72 months No
See also
  Status Clinical Trial Phase
Withdrawn NCT01913067 - Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC Phase 2
Completed NCT02662725 - Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases Phase 2
Completed NCT00406835 - Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases Phase 3
Completed NCT01724801 - Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer Phase 3
Completed NCT00219297 - Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02328300 - FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
Terminated NCT01324635 - Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors Phase 1
Terminated NCT01894633 - Study of Whole-brain Irradiation With Chloroquine for Brain Metastases Phase 2
Recruiting NCT02681549 - Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Phase 2
Terminated NCT02279992 - Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases Early Phase 1
Completed NCT01942980 - Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer Phase 3
Terminated NCT01363557 - Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis N/A
Active, not recruiting NCT05102747 - Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation. N/A
Recruiting NCT01891708 - VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer N/A
Completed NCT01508221 - Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis Phase 2
Completed NCT00587964 - Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Phase 2
Not yet recruiting NCT06462079 - Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases Phase 2
Not yet recruiting NCT02832635 - A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases Phase 2
Completed NCT01395407 - Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases Phase 1
Terminated NCT02433171 - Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery